In the past few years dimethylsulphoxide (DMSO) and colchicine have been suggested as methods of treatment for human amyloidosis. -5 In the present study we have looked at the effects of oral DMSO in 5 patients with biopsy-proved renal amyloidosis secondary to lepromatous leprosy, and of colchicine in 5 patients with primary amyloidosis.
Materials and methods
Patients were admitted to Hospital Lauro Souza Lima, a special hospital for leprosy in the City of Bauru, State of St Paulo, and classified by histological examination of biopsy specimens according to the Ridley and Jopling system. Five patients were classified as polar lepromatous and were included in the biopsy proven associated renal amyloidosis study. Patients with primary amyloid disease were followed up as outpatients at the Division of Immunology, Instituto Arnaldo Vieira Carvalho. by radioimunoassay as previously described by means of antiserum to amyloid protein SAA and 125I labelled amyloid protein (AA). The antiserum was prepared in rabbits by immunisation with purified AA.6 7 DMSO ('Pro-analyse' quality obtained from Carlo Erba, Brazil) was administered by mouth as 1-0 g in 5 ml distilled water 3 times daily for 6 consecutive months.
Patients with primary amyloidosis were given 1-0 g of colchicine daily for 6 consecutive months. Both groups of patients received exclusively DMSO or colchicine; no other form of treatment was given.
Results and discussion trend. All patients receiving DMSO had bad smelling breath (produced by partial conversion of DMSO into the radical sulphoxide). Table 2 shows the results with the use of colchicine in patients with primary amyloidosis. On the protocol used colchicine did not appear to alter renal function during 6 months of continuious use.
We concluded that in patients with generalised amyloidosis secondary to chronic infection the 421 can be drawn with regard to the amount of amyloid deposited in the kidney, since none of the patients was examined by biopsy again after treatment. The lack of correlation between renal function and serum SAA levels agrees with our previous experience.6 7 The possible mechanisms of action of DMSO is still poorly understood. It is known to be an anti-inflammatory agent with a mode of action which includes stabilisation of lysosomal membranes." The original work with DMSO in amyloidosis suggested that this compound could make the amyloid fibril soluble or accessible to proteolytic digestion.'
Colchicine has been used extensively in the treatment of amyloidosis associated with familial Mediterranean fever. 12 In a preliminary report Rubinow et al. 13 have suggested a beneficial effect on other forms of amyloidosis in man. Our experience has so far failed to show any beneficial effect of Table 2 The effect of colchicine on renal function after 3 and 6 months' daily administration: primary amyloidosis 
